HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

PEGBIO CO-B

8.830

+0.0100.11%

Volume:40.99M

Turnover:377.97M

Market Cap:3.45B

PE:-13.88

High:10.480

Open:9.260

Low:8.430

Close:8.820

52wk High:77.000

52wk Low:7.460

Shares:391.00M

HK Float Shares:284.00M

Volume Ratio:1.75

T/O Rate:14.43%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.636

ROE:-82.42%

ROA:-31.46%

PB:6.66

PE(LYR):-13.88

PS:-770.43

Loading ...

Overview Company News Filings

PegBio Trims Losses in 2025

MT Newswires Live

PegBio 2025 Annual Results: Net Loss Reduced to RMB208.55 Million, Cash Reserves Reach RMB467.54 Million Following Dual Fund-raisings

Bulletin Express

PEGBIO CO-B Reports Annual Results with R&D Investment of RMB50.387 Million and a Pipeline of Seven Chronic Disease Drug Candidates

Pegbio Co Ltd - FY Loss Attributable RMB208.4 Mln

THOMSON REUTERS

PegBio Wins China Approval for PB-119 Vepinetide Injection###

PegBio FY2025 net loss narrows 26.39% to RMB 208 million, equity jumps 6.81x to RMB 449 million

BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry

Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17

BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland China

PEGBIO CO-B (02565) Enters Exclusive Commercialization Pact with Tengrui Pharma for Paidakang in Mainland China, Targeting Over RMB 10 Billion in Cumulative Sales and Receiving Approximately HK$140 Million in Rights Payment

PegBio signs exclusive Paidakang commercialization deal with Tenry Pharmaceutical worth HKD140 million

Pegbio Co Ltd - Aggregate Commercialization Sales Target Over RMB10 Bln, Royalty About HK$140 Mln

THOMSON REUTERS

Pegbio Co Ltd - Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical for Paidakang in Mainland China

THOMSON REUTERS

Dual Boost from Policy and R&D! Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Rises Over 1%, Led by Biocytogen-B and PegBio Co-B

PEGBIO CO-B (02565) Schedules 23 Mar 2026 Board Meeting to Approve FY 2025 Results

Bulletin Express

PegBio schedules board meeting to approve 2025 annual results

Revised Title

PegBio's GLP-1 Candidate Completes First-in-Human Dosing

MT Newswires Live

PEGBIO CO-B (02565) Announces Completion of CR059 First-in-Human Trial with One-Month Clinical Observations

Bulletin Express

PEGBIO CO-B (02565) Reports One-Month Clinical Data from First-in-Human Trial of Next-Generation GLP-1 Candidate CR059

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/02565/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02565","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"PEGBIO CO-B","latestPrice":8.83,"timestamp":1779955711008,"preClose":8.82,"halted":0,"volume":40992550,"delay":0,"changeRate":0.001133786848072538,"floatShares":284000000,"shares":391000000,"eps":-0.6360584078838111,"marketStatus":"Not Yet Opened","change":0.01,"latestTime":"05-28 16:08:31","open":9.26,"high":10.48,"low":8.43,"amount":377971383,"amplitude":0.232426,"askPrice":8.83,"askSize":65000,"bidPrice":8.82,"bidSize":40050,"shortable":3,"etf":0,"ttmEps":-0.6360584078838111,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":0,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":8.82,"openAndCloseTimeList":[[1779931800000,1779940800000],[1779944400000,1779955200000]],"volumeRatio":1.7529818915693518,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02565\",,,,,undefined,":{"symbol":"02565","floatShares":284000000,"roa":"-31.46%","roe":"-82.42%","lyrEps":-0.636058,"volumeRatio":1.7529818915693518,"shares":391000000,"dividePrice":0,"high":10.48,"amplitude":0.232426,"preClose":8.82,"low":8.43,"week52Low":7.46,"pbRate":"6.66","psRate":"-770.43","week52High":77,"institutionHeld":0,"latestPrice":8.83,"committee":-0.237506,"eps":-0.6360584078838111,"divideRate":0,"volume":40992550,"delay":0,"ttmEps":-0.6360584078838111,"open":9.26,"prevYearClose":69,"prevWeekClose":12.94,"prevMonthClose":24.64,"prevQuarterClose":58,"fiveDayClose":15.38,"twentyDayClose":26.38,"sixtyDayClose":64.2},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02565\",params:#limit:5,,,undefined,":[{"market":"HK","date":"2026-03-23","symbol":"02565","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-26","symbol":"02565","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02565\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02565\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02565\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02565","date":"2026-05-27","current":-13.877669,"percent":0.869198,"low":-87.782868,"twenty":-73.777626,"median":-61.31588,"eighty":-19.117647,"high":-11.114373,"avg":-52.767999,"sd":24.924517,"marketCap":3449427312},"quantilePoints":[{"date":"2025-05-30","current":-12.743079,"twenty":-15.470266,"median":-13.542645,"eighty":-13.135794,"marketCap":3936746426},{"date":"2025-06-06","current":-11.987888,"twenty":-13.726785,"median":-12.740515,"eighty":-12.114178,"marketCap":3712892217},{"date":"2025-06-13","current":-11.23576,"twenty":-13.295707,"median":-12.114337,"eighty":-11.528404,"marketCap":3481318898},{"date":"2025-06-20","current":-11.30775,"twenty":-12.841258,"median":-11.963331,"eighty":-11.337793,"marketCap":3496757119},{"date":"2025-06-27","current":-12.421214,"twenty":-12.738977,"median":-11.541778,"eighty":-11.292079,"marketCap":3851836209},{"date":"2025-07-04","current":-13.963875,"twenty":-12.971799,"median":-11.987888,"eighty":-11.299391,"marketCap":4330421069},{"date":"2025-07-11","current":-13.604213,"twenty":-13.050401,"median":-12.199189,"eighty":-11.305737,"marketCap":4214634409},{"date":"2025-07-18","current":-16.956264,"twenty":-13.748078,"median":-12.438987,"eighty":-11.330282,"marketCap":5248995235},{"date":"2025-07-25","current":-19.006677,"twenty":-15.472199,"median":-12.742066,"eighty":-11.352726,"marketCap":5905119639},{"date":"2025-08-01","current":-19.199848,"twenty":-18.276271,"median":-12.906561,"eighty":-11.424474,"marketCap":5928276971},{"date":"2025-08-08","current":-20.51103,"twenty":-19.019895,"median":-13.05938,"eighty":-11.472546,"marketCap":6348968501},{"date":"2025-08-15","current":-39.959751,"twenty":-19.179784,"median":-13.542645,"eighty":-11.515029,"marketCap":12350577024},{"date":"2025-08-22","current":-41.864246,"twenty":-19.284777,"median":-13.964282,"eighty":-11.779976,"marketCap":12898633879},{"date":"2025-08-29","current":-41.44792,"twenty":-21.432837,"median":-14.946806,"eighty":-11.968242,"marketCap":10033166343},{"date":"2025-09-05","current":-50.678037,"twenty":-39.039264,"median":-17.018603,"eighty":-12.06328,"marketCap":12255314482},{"date":"2025-09-12","current":-58.538001,"twenty":-40.749762,"median":-18.438762,"eighty":-12.114019,"marketCap":14181548421},{"date":"2025-09-19","current":-57.311117,"twenty":-43.720929,"median":-18.952908,"eighty":-12.216159,"marketCap":13874467648},{"date":"2025-09-26","current":-63.587749,"twenty":-49.33228,"median":-19.070122,"eighty":-12.366345,"marketCap":15354038645},{"date":"2025-10-03","current":-60.149194,"twenty":-54.575673,"median":-19.16943,"eighty":-12.428323,"marketCap":14558420278},{"date":"2025-10-10","current":-60.121463,"twenty":-57.957283,"median":-19.199848,"eighty":-12.49878,"marketCap":14530503844},{"date":"2025-10-17","current":-60.168303,"twenty":-59.756564,"median":-19.2984,"eighty":-12.738571,"marketCap":14530503844},{"date":"2025-10-24","current":-61.301982,"twenty":-60.143648,"median":-20.51103,"eighty":-12.741458,"marketCap":14809668183},{"date":"2025-10-31","current":-69.345185,"twenty":-60.159469,"median":-22.018639,"eighty":-12.743079,"marketCap":16777776773},{"date":"2025-11-07","current":-59.401661,"twenty":-60.392128,"median":-34.33922,"eighty":-12.780248,"marketCap":14363005241},{"date":"2025-11-14","current":-72.819022,"twenty":-61.035505,"median":-39.959751,"eighty":-12.906561,"marketCap":17657144441},{"date":"2025-11-21","current":-72.852961,"twenty":-61.301982,"median":-40.866122,"eighty":-12.943343,"marketCap":17657144441},{"date":"2025-11-28","current":-82.344376,"twenty":-62.346137,"median":-42.423494,"eighty":-13.014482,"marketCap":20030041323},{"date":"2025-12-05","current":-72.063717,"twenty":-63.355663,"median":-45.122001,"eighty":-13.104279,"marketCap":17559436923},{"date":"2025-12-12","current":-74.217813,"twenty":-64.460997,"median":-48.969529,"eighty":-13.233973,"marketCap":18117765601},{"date":"2025-12-19","current":-71.875632,"twenty":-65.413889,"median":-52.055133,"eighty":-13.542645,"marketCap":17587353357},{"date":"2025-12-24","current":-73.927127,"twenty":-69.382811,"median":-55.337969,"eighty":-13.579586,"marketCap":18145682035},{"date":"2026-01-02","current":-79.895405,"twenty":-70.540926,"median":-57.311117,"eighty":-13.748078,"marketCap":19687798475},{"date":"2026-01-09","current":-85.854057,"twenty":-72.056904,"median":-58.941314,"eighty":-13.964201,"marketCap":21208805289},{"date":"2026-01-16","current":-80.413876,"twenty":-72.839385,"median":-59.401661,"eighty":-14.164153,"marketCap":19929453763},{"date":"2026-01-23","current":-77.735339,"twenty":-73.262106,"median":-59.808211,"eighty":-14.656731,"marketCap":19247132950},{"date":"2026-01-30","current":-73.838267,"twenty":-73.550435,"median":-60.0941,"eighty":-15.472199,"marketCap":18365801899},{"date":"2026-02-06","current":-69.490034,"twenty":-73.32273,"median":-60.154331,"eighty":-16.538679,"marketCap":17328105662},{"date":"2026-02-13","current":-71.473742,"twenty":-73.562339,"median":-60.192909,"eighty":-17.006135,"marketCap":17925136373},{"date":"2026-02-20","current":-71.065981,"twenty":-73.716985,"median":-60.392128,"eighty":-17.056006,"marketCap":17797201221},{"date":"2026-02-27","current":-72.540901,"twenty":-73.438012,"median":-60.796223,"eighty":-17.950543,"marketCap":18365801899},{"date":"2026-03-06","current":-68.036226,"twenty":-73.352041,"median":-61.160082,"eighty":-18.384598,"marketCap":17086450373},{"date":"2026-03-13","current":-60.794114,"twenty":-73.299371,"median":-60.919795,"eighty":-18.597951,"marketCap":15338003289},{"date":"2026-03-20","current":-67.303035,"twenty":-73.275932,"median":-61.206433,"eighty":-18.84686,"marketCap":16915870170},{"date":"2026-03-27","current":-68.867925,"twenty":-73.269478,"median":-61.274827,"eighty":-18.985169,"marketCap":16247764373},{"date":"2026-04-02","current":-85.055535,"twenty":-73.278872,"median":-61.433108,"eighty":-19.026504,"marketCap":20163286400},{"date":"2026-04-10","current":-78.454069,"twenty":-73.369897,"median":-61.662876,"eighty":-19.045802,"marketCap":18741784705},{"date":"2026-04-17","current":-76.94604,"twenty":-73.948705,"median":-62.45145,"eighty":-19.079188,"marketCap":18389252284},{"date":"2026-04-24","current":-60.4786,"twenty":-73.948705,"median":-62.528681,"eighty":-19.126247,"marketCap":14454535592},{"date":"2026-05-15","current":-17.642518,"twenty":-73.927127,"median":-62.346137,"eighty":-19.115451,"marketCap":4376314243},{"date":"2026-05-22","current":-20.448357,"twenty":-73.838267,"median":-61.433108,"eighty":-19.16943,"marketCap":5060724424},{"date":"2026-05-27","current":-13.89213,"twenty":-73.777626,"median":-61.31588,"eighty":-19.117647,"marketCap":3449427312}],"updateTime":1779991888943},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02565\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621779352","title":"PegBio Trims Losses in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2621779352","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621779352?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:00","pubTimestamp":1774256439,"startTime":"0","endTime":"0","summary":"PegBio  booked 208.4 million yuan in attributable loss for 2025, narrowing from 283.4 million yuan in 2024, according to a Hong Kong bourse filing Monday.Loss per share was 0.55 yuan, compared with 0.77 yuan in the prior year.The firm did not generate any revenue during the year or in 2024.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191587925","title":"PegBio 2025 Annual Results: Net Loss Reduced to RMB208.55 Million, Cash Reserves Reach RMB467.54 Million Following Dual Fund-raisings","url":"https://stock-news.laohu8.com/highlight/detail?id=1191587925","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191587925?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:42","pubTimestamp":1774255349,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (PEGBIO CO-B, 02565) released its audited results for the year ended 31 December 2025. Financial Performance   • Loss for the year narrowed 26.4% to RMB208.55 million, versus...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180038614","title":"PEGBIO CO-B Reports Annual Results with R&D Investment of RMB50.387 Million and a Pipeline of Seven Chronic Disease Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=1180038614","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180038614?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:42","pubTimestamp":1774255342,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced its annual results for the period ending December 31, 2025. The Group recorded other net income of RMB189,000 and research and development expenses of RMB50.387 million....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","399441","BK1161","161726","BK4588","BK4585","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621469775","title":"Pegbio Co Ltd - FY Loss Attributable RMB208.4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2621469775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621469775?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:32","pubTimestamp":1774254727,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B05N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775455","title":"PegBio Wins China Approval for PB-119 Vepinetide Injection###","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775455","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775455?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:31","pubTimestamp":1774254699,"startTime":"0","endTime":"0","summary":"Pegbio said its PB-119 product received marketing approval from China’s National Medical Products Administration in November 2025, enabling a shift from development to commercialization planning.The company expects PB-119 to begin commercial sales in 1H 2026, positioning it to become Pegbio’s first revenue-generating product.Pegbio is pursuing a partnership-based commercialization approach in mainland China after a prior marketing collaboration for PB-119 was terminated in June 2025.The company reported no revenue from PB-119 as of the announcement date and ended 2025 with CNY 467.5 million in cash and cash equivalents to support launch execution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original con","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9pF429:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621775453","title":"PegBio FY2025 net loss narrows 26.39% to RMB 208 million, equity jumps 6.81x to RMB 449 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621775453","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621775453?lang=en_us&edition=fundamental","pubTime":"2026-03-23 16:31","pubTimestamp":1774254694,"startTime":"0","endTime":"0","summary":"PegBio published an annual results announcement for the year ended Dec. 31, 2025.Loss from operations narrowed 26.73% to RMB205.77 million, and loss for the year narrowed 26.4% to RMB208.55 million.Basic and diluted loss per share improved 28.57% to RMB0.55, while the company reported no revenue from product sales.Total assets rose more than 1.7x to RMB599.23 million, and cash and cash equivalents rose more than 1.7x to RMB467.54 million.PB-119 received marketing approval from China’s NMPA in November 2025, and PegBio expects commercial sales to begin in the first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information S","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL7sY1nP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620741213","title":"BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry","url":"https://stock-news.laohu8.com/highlight/detail?id=2620741213","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620741213?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:34","pubTimestamp":1773718440,"startTime":"0","endTime":"0","summary":"BUZZ-PegBio jumps most in 7 months on deal with Shanghai Tenry** China-based PegBio Co 2565.HK shares jump as much as 20.3% to HK$65.15, set for biggest one-day pct rise since August 15, 2025 ** Innovative therapies developer's stock hit the highest point since March 9** PegBio said it has entered into an exclusive commercialization collaboration with Shanghai Tenry Pharmaceutical for the company's core product Paidakang for treatment of type 2 diabetes in China ** Tenry Pharmaceutical will pay royalty totaling HK$140 million  to the company - Co** YTD, stock down 17.6%, while Hang Seng Biotech Index .HSBIO climbs 3.8%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL1N40503X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192730058","title":"Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1192730058","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192730058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:18","pubTimestamp":1773710304,"startTime":"0","endTime":"0","summary":"Major Corporate Developments: Hengrui Pharma (01276) announced that its SHR-1819 injection and SHR-1905 injection have received drug clinical trial approval notices. Henlius (02696) disclosed that...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"86c6cd7c917d7913316e328a31a00c76","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1521","HK0000320264.USD","02696","01276","01428","BK1197","BK1606","LU1023057109.AUD","VXUS","BK1515","06688","HK0000165453.HKD","HK0000306701.USD","LU0359201612.USD","HK0000320223.HKD","BK4588","00874","BK1161","BK1191","HK0000306685.HKD","LU2543165471.USD","BK1147","LU0359201885.HKD","LU0359202008.SGD","02565","BK4585"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619463298","title":"BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2619463298","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619463298?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:54","pubTimestamp":1773665640,"startTime":"0","endTime":"0","summary":"BRIEF-PegBio Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical For Paidakang In Mainland ChinaMarch 16  - PegBio Co Ltd 2565.HK:ENTERS EXCLUSIVE COMMERCIALIZATION COLLABORATION WITH TENRY PHARMACEUTICAL FOR PAIDAKANG IN MAINLAND CHINAAGGREGATE COMMERCIALIZATION SALES TARGET OVER RMB10 BILLION, ROYALTY ABOUT HK$140 MILLIONFurther company coverage: 2565.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172606217","title":"PEGBIO CO-B (02565) Enters Exclusive Commercialization Pact with Tengrui Pharma for Paidakang in Mainland China, Targeting Over RMB 10 Billion in Cumulative Sales and Receiving Approximately HK$140 Million in Rights Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=1172606217","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172606217?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:54","pubTimestamp":1773658483,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced the signing of a strategic cooperation agreement with Shanghai Tengrui Pharmaceutical Co., Ltd. for the commercialization of its core product, Paidakang, in Mainland...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK1161","BK1191","BK4585","02565","399441","BK4581","BK1574","BK4588","01477","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619547714","title":"PegBio signs exclusive Paidakang commercialization deal with Tenry Pharmaceutical worth HKD140 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619547714","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619547714?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658231,"startTime":"0","endTime":"0","summary":"PegBio entered a strategic cooperation agreement with Tenry Pharmaceutical for the commercialization of Paidakang in mainland China. Under the arrangement, Tenry will handle exclusive commercialization and promotion activities for the product in mainland China. The companies set a cumulative sales target of more than CNY 10 billion for Paidakang under the commercialization plan. Tenry will pay PegBio royalties totaling about HKD 140 million, which are expected to be paid within the current year. Sales revenue for Paidakang in mainland China will be recognized by PegBio, while PegBio retains intellectual property and overseas market interests for the product.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7S60br:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619547904","title":"Pegbio Co Ltd - Aggregate Commercialization Sales Target Over RMB10 Bln, Royalty About HK$140 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2619547904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619547904?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658225,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619454200","title":"Pegbio Co Ltd - Enters Exclusive Commercialization Collaboration With Tenry Pharmaceutical for Paidakang in Mainland China","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454200","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619454200?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658225,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121911076","title":"Dual Boost from Policy and R&D! Huabao Fund's Hong Kong Stock Connect Innovative Drug ETF (520880) Rises Over 1%, Led by Biocytogen-B and PegBio Co-B","url":"https://stock-news.laohu8.com/highlight/detail?id=1121911076","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121911076?lang=en_us&edition=fundamental","pubTime":"2026-03-12 10:11","pubTimestamp":1773281490,"startTime":"0","endTime":"0","summary":"On the morning of March 12, the Hong Kong Stock Connect Innovative Drug ETF (520880) showed steady performance during the trading session, with its on-market price currently up 1.23%. The fund's...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["520880","399441","02315","BK1161","688796","BK4581","02565","XBI","BK4585","BK4588","BK0216","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149352945","title":"PEGBIO CO-B (02565) Schedules 23 Mar 2026 Board Meeting to Approve FY 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1149352945","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149352945?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:42","pubTimestamp":1773218569,"startTime":"0","endTime":"0","summary":"PEG Bio Co., Ltd. (PEGBIO CO-B, stock code 02565) announced that its board of directors will convene on 23 March 2026. The agenda includes reviewing and approving the Group’s audited annual results...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618912336","title":"PegBio schedules board meeting to approve 2025 annual results","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912336","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618912336?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217859,"startTime":"0","endTime":"0","summary":"PegBio’s board will meet on March 23, 2026 to consider and approve the group’s annual results for the year ended December 31, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL72pwYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178409030","title":"Revised Title","url":"https://stock-news.laohu8.com/highlight/detail?id=1178409030","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178409030?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:58","pubTimestamp":1773140298,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) has announced that the board lot size for its H shares, each with a par value of RMB 1.00, traded on the Main Board of The Stock Exchange of Hong Kong Limited will be adjusted....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565","BK1161","BK4585","399441","BK4588","BK4581","XBI","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618151616","title":"PegBio's GLP-1 Candidate Completes First-in-Human Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2618151616","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618151616?lang=en_us&edition=fundamental","pubTime":"2026-03-09 10:54","pubTimestamp":1773024857,"startTime":"0","endTime":"0","summary":"PegBio  said its next-generation GLP-1 receptor agonist CR059 has completed single-dose administration in a first-in-human clinical trial and generated one-month clinical observations, according to a March 6 Hong Kong bourse filing.Shares of the biopharmaceutical company were down nearly 2% in Monday morning trade.The study is evaluating the safety, tolerability, and pharmacokinetic and pharmacodynamic characteristics of CR059 in patients with type 2 diabetes mellitus, the company said.Preliminary observations four weeks after a single dose showed improvements in glycated hemoglobin, fasting blood glucose, and overall glucose control, PegBio said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","02565","GLP","BK4590","BK4144"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142171906","title":"PEGBIO CO-B (02565) Announces Completion of CR059 First-in-Human Trial with One-Month Clinical Observations","url":"https://stock-news.laohu8.com/highlight/detail?id=1142171906","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142171906?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:23","pubTimestamp":1772789011,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. (02565) announced that CR059, a next-generation GLP-1 receptor agonist developed with circular RNA protein replacement technology and an AI-assisted molecular design platform, has...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100684135","title":"PEGBIO CO-B (02565) Reports One-Month Clinical Data from First-in-Human Trial of Next-Generation GLP-1 Candidate CR059","url":"https://stock-news.laohu8.com/highlight/detail?id=1100684135","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100684135?lang=en_us&edition=fundamental","pubTime":"2026-03-06 17:12","pubTimestamp":1772788377,"startTime":"0","endTime":"0","summary":"PEGBIO CO-B (02565) announced that CR059, its novel GLP-1 receptor agonist developed using a circular RNA (CircRNA) protein replacement technology and an AI-assisted molecular design platform, has...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","BK1161","BK4588","161726","BK4585","02565","GLP","BK4144","399441","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":72,"code":"91000000","status":"200"}]}}